Thu, November 17, 2011
Wed, November 16, 2011
Tue, November 15, 2011
[ Tue, Nov 15th 2011 ] - Market Wire
3rd Annual Unity Brew
Mon, November 14, 2011
Sun, November 13, 2011
Sat, November 12, 2011
Fri, November 11, 2011
Thu, November 10, 2011
[ Thu, Nov 10th 2011 ] - Market Wire
Third Quarter 2011 Highlights

Market Maker Surveillance Report. PSDV, ATPG, FFHL, CNGL, GLGL, ALIM, Losing Stocks With Lowest Price Friction For Monday, Nov


//stocks-investing.news-articles.net/content/201 .. s-with-lowest-price-friction-for-monday-nov.html
Published in Stocks and Investing on Monday, November 14th 2011 at 18:00 GMT by WOPRAI   Print publication without navigation


November 14, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3613 companies with "abnormal" market making, 1801 companies with positive Friction Factors and 4362 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. PSIVIDA CORP (NASDAQ:PSDV), ATP OIL & GAS CORPORATION (NASDAQ:ATPG), Fuwei Films (Holdings) Co. Ltd. - ORDINARY SHARES (NASDAQ:FFHL), CHINA NUTRIFRUIT GROUP LTD (AMEX:CNGL), GLG LIFE TECH CORP (NASDAQ:GLGL), ALIMERA SCIENCES INC (NASDAQ:ALIM). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     PSDV       $-0.440      -21.48%      216,697         42.65%       289,669         57.01%       -72,972         -1,658  
     ATPG       $-1.050      -15.56%      4,051,976       48.06%       4,370,862       51.84%       -318,886        -3,037  
     FFHL       $-0.370      -18.59%      25,669          26.53%       63,886          66.03%       -38,217         -1,033  
     CNGL       $-0.820      -39.81%      45,137          14.28%       64,572          20.43%       -19,435         -237    
     GLGL       $-0.400      -17.24%      124,400         48.45%       132,338         51.55%       -7,938          -198    
     ALIM       $-0.340      -17.35%      896,258         46.14%       1,045,284       53.81%       -149,026        -4,383  
Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows PSDV with a dollar loss Monday of $-0.44000 and a Friction Factor of -1,658 shares. That means that it only took 1,658 more shares of selling than buying to move PSDV lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

PSIVIDA CORP (NASDAQ:PSDV) - pSivida Corp., together with its subsidiaries, develops drug delivery products that are administered by implantation, injection, or insertion. The companys lead product candidate is Iluvien, which is in Phase III clinical trials and delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), a cause of vision loss. It is also conducting Phase II clinical trials with Iluvien in wet and dry age-related macular degeneration. In addition, the companys products include Retisert, an intravitreal drug implant for the treatment of chronic non-infectious posterior uveitis; and Vitrasert for cytomegalovirus retinitis, a blinding eye disease that occurs in individuals with advanced AIDS. It is developing a series of additional miniaturized, bioerodible technologies, including BioSilicon technology, which is nano-structured porous silicon designed for use as a drug delivery platform; and Medidur technology, a miniaturized, injectable, sustained-release drug delivery system to advance the treatment of medical conditions in critical areas, such as ophthalmology, oncology, and cardiology. Further, the companys BioSilicon product candidates includes BrachySil, a brachytherapy product in development for the treatment of solid tumors; and completed an initial safety study of BrachySil for the treatment of pancreatic cancer and a dose ranging study. It has strategic collaborations with Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.

ATP OIL & GAS CORPORATION (NASDAQ:ATPG) - ATP Oil & Gas Corporation engages in the acquisition, development, and production of oil and natural gas properties in the Gulf of Mexico, the United Kingdom, and the Dutch Sectors of the North Sea. As of December 31, 2009, it had estimated net proved reserves of approximately 135.2 million barrels of crude oil or other liquid hydrocarbons equivalent (MMBoe), of which approximately 91.3 MMboe were in the Gulf of Mexico and 43.9 MMBoe were in the North Sea. The company also owned leasehold and other interests in 62 offshore blocks and 104 wells, including 19 subsea wells in the Gulf of Mexico, as well as had interests in 11 blocks and 3 company-operated subsea wells in the North Sea. It had reserves of approximately 77.9 million barrels of crude oil or other liquid hydrocarbons and 343.3 billion cubic feet of natural gas. The company was founded in 1991 and is based in Houston, Texas.

Fuwei Films (Holdings) Co. Ltd. - ORDINARY SHARES (NASDAQ:FFHL) - Fuwei Films (Holdings) Co. Ltd. - ORDINARY SHARES

CHINA NUTRIFRUIT GROUP LTD (AMEX:CNGL) - China Nutrifruit Group Limited, through its subsidiary, Longheda, produces specialty fruit based products in the Peoples Republic of China. The company develops, processes, markets, and distributes various food products processed primarily from specialty fruits, including golden berries, crab apples, blueberries, and raspberries. Its products include fruit concentrate, nectar, and glazed fruits, as well as fresh fruits. The company sells its processed fruit products to food producers for further processing into fruit juice and other fruit related foods; and fresh fruits to fruit supermarkets. It offers its products through a sales and distribution network covering 20 provinces and 47 cities in the People's Republic of China. The company is based in Daqing, the Peoples Republic of China.

GLG LIFE TECH CORP (NASDAQ:GLGL) - GLG Life Tech Corporation engages in the research and development, growing, refining, production, and distribution of stevia extract to the food and beverage industry worldwide. Stevia extract is a natural sweetener extracted from the stevia plant. GLG Life Tech Corporation has a strategic alliance with Cargill, Incorporated to supply stevia extract to Cargill for manufacturing a natural, zero-calorie sweetener brand called TRUVIA. The company was founded as a public company in 2005 and is headquartered in Vancouver, Canada.

ALIMERA SCIENCES INC (NASDAQ:ALIM) - Alimera Sciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of ophthalmic pharmaceuticals. It develops pharmaceuticals for diseases affecting the back of the eye or retina. The companys product candidates include Iluvien, an intravitreal insert that provides a sustained therapeutic effect for up to 36 months in the treatment of diabetic macular edema; or DME, a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness, as well as other ophthalmic diseases, such as the wet form of age-related macular degeneration (AMD), the dry form of AMD, and retinal vein occlusion. It also conducts testing on two classes of Nicotinamide Adenine Dinucleotide Phosphate oxidase inhibitors. The company was founded in 2003 and is headquartered in Alpharetta, Georgia.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net


Publication Contributing Sources